Summary
We reviewed the records of 315 patients with rheumatoid arthritis (RA) treated with low-dose methotrexate (MTX) and evaluated the conditions contributing to thrombocytopenia. Thirteen out of 315 patients with RA presented with low platelet counts (≤100.000/mm3). The age of these patients (51 ± 12.6 years) did not correlate with thrombocytopenia (r=0.211, p>0.05).
Thrombocytopenia resulted from coadministration of MTX and NSAID or multiple drug interactions. We observed a significant (r=0.48, p<0.05) increase of discontinuation of NSAID's but not of MTX therapy (r=0.42, p>0.05) with a mounting weekly dosage of MTX (12.5±5 mg orally). There was a significant correlation between this weekly dosage of MTX coadministered on the same day with NSAID and thrombocytopenia (r=0.6, p<0.05).
In most cases (9/13) MTX was not or just temporarily withdrawn. Three of the remaining patients had multiple drug interactions. Reintroduction of low dose MTX treatment in patients having had thrombocytopenia could be performed safely, if thrombocytopenia occurred as a result of concomitant application of MTX and NSAID and no other multiple drug interactions. Preferably, MTX and NSAID should be given to these risk patients on separate days or intervals considering half time clearance of NSAIDs. This procedure has prevented the reoccurrence of thrombocytopenia and controlled further drug interactions of NSAIDs and MTX in our patients.
Similar content being viewed by others
References
Willkens, R.F., Watson, M.A., Paxson, C.S. Low dose pulse methotrexate therapy in rheumatoid arthritis. J Rheumatol 1980, 7, 501–505.
Steinsson, K., Weistein, A., Korn, J., Abeles, M. Low dose methotrexate in rheumatoid arthritis. J Rheumatol 1982, 9, 860–866.
Anderson, P.A., West S.G., O'Dell, J.R., Via, C.S., Claypool, R.G., Kotzin, B.L. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 103, 1985, 489–496.
Weinblatt, M.E., Weissman, B.N., Holdsworth, D.E., Fraser, P.A., Maier, A.L., Falchuk, K.R., Coblyn, J.S. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis and Rheumatism 1992, 35 (2) 129–137.
Rau, R., Karger, T., Herborn, G., Frenzel, H. Liver biopsy findings in patients with rheumatoid arthritis undergoing long-term treatment with methotrexate. J Rheumatol 1989, 16, 489–493.
Robes, M.W., Bennett, G.A., Cobb, S., Jacox, R., Jessar, R.A. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Diss 1958, 175–176
Edelman, J., Russel, A.S., Biggs, D.F. Methotrexate levels a guide of therapy? Clin Exp Rheum 1983, 1, 153–156.
MacKinnon, S.K., Starkebaum, G., Willkens, R. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1985, 15, 119–126
Malprin, K.M., Fukui, D., Ohkawara A. Blood levels of methotrexate and the treatment of psoriasis. Arch Dermatol 1971, 103, 243–249.
Ferrazzini, G., Klein, J., Sulh, H. et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 1990, 117, 823–826.
Groenendal, H., Rampen, F.H.J. Methotrexate and trimethoprim- sulphamethoxazole — a potentially hazardous combination. Clin Exp Dermatol 1990, 15, 358–360
Al-Awadhi, A., Dale, P., McKendry, R.J. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheumatol 1993, 20(7), 1121–1125.
Alarcón, G.S., Tracy, I.C., Blackburn, D. Methotrexate in rheumatoid arthritis. Toxic effect as the major factor in limiting long-term treatment. Arthritis Rheum 1989, 32, 671–676.
Rooney, T.W., Furst, D.E. Comparison of toxicity in methotrexate treated rheumatoid arthritis patients also taking aspirin or other NSAID (abstract). Arthritis Rheum 1986, 29(4), 76
Shupack, J.L., Webster, G.F. Pancytopenia following low-dose oral methotrexate therapy for psoriasis. JAMA 1988, 259, 3594–3596.
Kevat, S.G., McCarthy, P.J., Hill, W.R. et al. Pancytopenia induced by low-dose methotrexate for rheumatoid arthritis. Aust NZ J Med 1988, 18, 697–700.
Furst, D.E., Herman, R.A., Koehnke, R. et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990, 79, 782–786.
Clive, D.M., Stoff, J.S. Renal syndromex associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984, 310, 563–572.
Steele, W.H., Lawrence, J.R., Stuart, J.F.B. The protein binding of methotrexate by the serum of normal subjects. Eur J Clin Pharmacol 1979, 15, 363–366.
Claudepierre, P., Urien, S., Chevalier, X., Chassany, O., Larget-Piet, B., Tillement, J.P. Methotrexate serum binding in rheumatoid arthritis. Int J Clin Pharmacol Ther 1994, 32(3), 113–115.
Bannwarth, B., Labat, L., Moride, Y., Schaeverbeke, T. Methotrexate in rheumatoid arthritis. An update. Drugs. 1994, 47(1), 25–50.
Frenia, M.L., Long, K.S. Methotrexate and nonsteroidal anti-inflammatory drug interactions. Ann Pharmacother 1992, 26(2), 234–237.
Stewart, F., Fleming, R.A., Arkin et al. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther 1990, 47, 540–546.
Tracy, T.S., Krohn, K., Jones, D.R., Bradley, J.D., Hall, S.D., Brater, D.C. The effects of salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992, 42(2), 121–125.
Tracy, T.S., Worster, T., Bradley, J.D., Greene, P.K., Brater, D.C. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1994, 37(5), 453–456.
Steinbrocker, O. Criteria in rheumatoid arthritis. JAMA 1949, 140, 659–662
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Franck, H., Rau, R. & Herborn, G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol 15, 266–270 (1996). https://doi.org/10.1007/BF02229705
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02229705